Stock selection in the information technology and financials sectors contributed to the relative performance of the fund.

AbbVie has delivered strong returns and dividend growth, with solid prospects but notable risks creating near-term ...

In a report released today, Gary Nachman from Raymond James reiterated a Buy rating on AbbVie, with a price target of $236.00. The company’s shares closed yesterday at $209.50. Take advantage of ...

Three Motley Fool contributors think they've found unstoppable dividend stocks to buy right now. Here's why they picked ...